Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.
- DOI
- 10.1016/j.ejmech.2026.119274
- Published
- 2026 Aug 25
- Container
- European journal of medicinal chemistry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejmech.2026.119274,
title = {Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.},
author = {He Z and Zhang Y and Zhan S and Cao T and Bai W and Zhou B and Yu J and Zeng H and Zhou J and Tian F and Chen X and Zhang S and Zheng M and Wu X},
year = {2026},
journal = {European journal of medicinal chemistry},
doi = {10.1016/j.ejmech.2026.119274},
url = {https://doi.org/10.1016/j.ejmech.2026.119274}
}RIS
TY - JOUR TI - Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy. AU - He Z AU - Zhang Y AU - Zhan S AU - Cao T AU - Bai W AU - Zhou B AU - Yu J AU - Zeng H AU - Zhou J AU - Tian F AU - Chen X AU - Zhang S AU - Zheng M AU - Wu X PY - 2026 JO - European journal of medicinal chemistry DO - 10.1016/j.ejmech.2026.119274 UR - https://doi.org/10.1016/j.ejmech.2026.119274 ER -
APA
Z, H., Y, Z., S, Z., T, C., W, B., B, Z., J, Y., H, Z., J, Z., F, T., X, C., S, Z., M, Z., & X, W. (2026). Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy.. European journal of medicinal chemistry. https://doi.org/10.1016/j.ejmech.2026.119274
Source records
- pubmed · retrieved 2026-09-25T15:00:16.440Z